Figure 3.

TLR2^KO BC cells display impaired tumorigenicity. (a) Tumor-free survival and (b) mean tumor volume of TLR2^WT and TLR2^KO mice (N = 6 per group, from 2 independent experiments) injected orthotopically with 1 × 10⁶ WT-874 or KO-M26 cells. (c) Mean tumor volume of BALB/c mice orthotopically injected with 1 × 10⁴ 4T1 cells left untreated (N = 5), transfected with scrambled siRNAs (N = 7) or siRNAs to TLR2 (N = 7). (d) Mean tumor volume of NSG mice injected orthotopically with 1 × 10⁶ WT-874, WT-879, WT-880, KO-C26, KO-M26 or KO-E26 cells (N = 6 per group from two independent experiments). (a) Log-rank (Mantel-Cox) of KO-M26 cells injected into TLR2^WT and TLR2^KO mice vs WT-874 cells injected into TLR2^WT mice. (b) two-way ANOVA test.